Loading clinical trials...
Loading clinical trials...
Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults With Hereditary Angioedema (HAE)
Conditions
Interventions
Biological NTLA-2002
Normal Saline IV Administration
Locations
9
Australia
Clinical Trial Site
Campbelltown, Australia
Clinical Trial Site
Grenoble, France
Clinical Trial Site
Lille, France
Clinical Trial Site
Paris, France
Clinical Trial Site
Berlin, Germany
Clinical Trial Site
Frankfurt, Germany
Start Date
December 10, 2021
Primary Completion Date
April 4, 2024
Completion Date
July 1, 2026
Last Updated
March 24, 2026
NCT06960213
NCT07001280
NCT07298447
NCT06842823
NCT06573723
NCT07046806
Lead Sponsor
Intellia Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions